Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: Occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial
D. Craig Miller(Harvard University), Craig R. Smith(University of Arizona), E. Murat Tuzcu(Cleveland Clinic), Michael J. Mack(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Susheel Kodali(Columbia University Irving Medical Center), Eugene H. Blackstone(Cleveland Clinic), John G. Webb(St. Paul's Hospital), Jeevanantham Rajeswaran(Cleveland Clinic Lerner College of Medicine), Jeffrey W. Moses(Good Samaritan University Hospital), Samir Kapadia(Cleveland Clinic), Martin B. Leon(Columbia University Irving Medical Center), Lars G. Svensson(Cleveland Clinic), William N. Anderson(Edwards Lifesciences (United States))
Cited by 349
Related Papers
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
|New England Journal of Medicine|2016|5.1k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k
EuroSCORE II
|European Journal of Cardio-Thoracic Surgery|2012|2.9k